Glucolipotoxicity-Mediated
Type 2 Diabetes Assay
REVEALING YOUR DRUG POTENTIAL ON GLUCOLIPOTOXICITY USING A UNIQUE PATHOPHYSIOLOGICAL ASSAY
Unlock your beta-cell protection-mediated glucolipotoxicity strategy
APPLICATIONS
Glucolipotoxicity is an important phenomenon combining the deleterious effects of elevated glucose and fatty acid levels on pancreatic β-cell function and survival. It is a key element in Human Type 2 diabetes’ pathophysiology. It impairs insulin secretion, inhibits insulin gene expression and induces β-cell death by apoptosis.
Glucolipotoxicity assay combines strengths of 2 models: One physiological EndoC-βH5® model and one sensitive pathological GLTx EndoC-βH5® model. This assay enables you to assess the pharmacological efficacy of your drug discovery strategies aiming to protect human beta cells and slow the progression of insulin secretion dysfunction due to glucolipotoxicity.
GLTx assay: 2 models of glucolipotoxicity
The assay reproduces the clinically observed response of human pancreatic beta cells to high glucose and free fatty acid sensitization
ASSAY CONCEPT
RESULTS
One physiological (WT) & one sensitive pathological (GLTx) model
Beta cell loss induced by 10 days of glucolipotoxicity in WT (left) and GLTx (right) EndoC-βH5® models
Physiological WT EndoC-βH5® is a long window response model (>10 days)
Sensitive pathological GLTx EndoC-βH5® is an early response model (2-3 days)
HAVE A PROJECT IN MIND?
Human Cell Design team of experts can offer you tailored assays on GLTx EndoC-βH5® derived cell models.
